S-1/A: HeartFlow IPO: AI-Powered CAD Diagnosis Seeks $200M

HeartFlow, Inc., a pioneer in AI-powered coronary artery disease diagnosis, files for an initial public offering of 12.5 million shares, targeting a price range of $15.00 to $17.00 per share.

Summary

• HeartFlow, Inc. is offering 12,500,000 shares of common stock in its initial public offering, with an expected price range of $15.00 to $17.00 per share.
• Underwriters have a 30-day option to purchase up to an additional 1,875,000 shares of common stock.
• Net proceeds from the offering are estimated at approximately $180.5 million (or $208.4 million if the underwriters' option is fully exercised), based on the $16.00 midpoint price.
• Proceeds will be used to repay $50.0 million (or $55.0 million) of the 2024 Credit Agreement indebtedness and pay approximately $6.2 million in related fees.
• The remaining net proceeds will fund sales and marketing efforts, research and product development activities, and other general corporate purposes.
• The HeartFlow Platform, leveraging AI and computational fluid dynamics, provides a non-invasive solution for diagnosing and managing coronary artery disease (CAD).
• The platform has been used to assess CAD in over 400,000 patients as of March 31, 2025, including 132,000 in 2024 alone.
• Revenue for the year ended December 31, 2024, was $125.8 million, representing 44% year-over-year growth from $87.2 million in 2023.
• Revenue for the three months ended March 31, 2025, was $37.2 million, representing 39% growth over $26.8 million in the prior year period.
• Gross margins were 75% for the year ended December 31, 2024 (an 8 percentage point increase), and 75% for the three months ended March 31, 2025 (a 3 percentage point increase).
• Net losses were $96.4 million for 2024 and $32.3 million for the three months ended March 31, 2025.
• The accumulated deficit reached $1.0 billion as of March 31, 2025.
• Preliminary estimated revenue for Q2 2025 is $42.9 million to $43.4 million (38% to 40% increase year-over-year), with an estimated gross margin of 74.5% to 75.5%.
• Cash and cash equivalents are expected to be $80.2 million as of June 30, 2025, down from $109.8 million as of March 31, 2025.
• The estimated U.S. market opportunity for HeartFlow FFRCT Analysis and HeartFlow Plaque Analysis is approximately $5 billion, covering 3.1 million and 5.5 million eligible patients, respectively.
• HeartFlow FFRCT Analysis is reimbursed under a dedicated Category I CPT code, effective January 1, 2024, with coverage policies representing approximately 99% of covered lives in the United States.
• HeartFlow Plaque Analysis has a new Category I CPT code, effective January 1, 2026, and is covered by all seven Medicare administrative contractors (MACs).

Sentiment

Score: 4

Explanation: While HeartFlow presents a compelling technological solution to a significant global health problem, backed by strong clinical evidence and growing market adoption, the company's substantial and increasing net losses, accumulated deficit, and projected cash burn raise significant financial concerns. The IPO provides much-needed capital, but the immediate dilution for new investors and the ongoing risks related to reimbursement changes and product dependence temper the overall positive outlook from its innovative technology and market potential.

Positives

• Achieved significant revenue growth: 44% year-over-year in 2024 ($125.8 million) and 39% in Q1 2025 ($37.2 million).
• Demonstrated expanding gross margins: 75% in 2024 (up 8 percentage points) and 75% in Q1 2025 (up 3 percentage points), driven by AI automation and efficiency improvements.
• Identified a large addressable market opportunity: Estimated $5 billion in the U.S. for current products, with a potential for expansion into the asymptomatic CAD market (approximately 200 million people globally).
• Possesses a robust and compelling portfolio of clinical evidence: Over 100 clinical studies, 130,000+ patients, and 600+ peer-reviewed publications validate the platform's accuracy, clinical utility, and economic benefits.
• Clinical trials (e.g., PRECISE) showed HeartFlow FFRCT Analysis was 78% more likely to identify patients needing revascularization and resulted in a 69% reduction in unnecessary invasive procedures.
• Benefits from established reimbursement coverage: HeartFlow FFRCT Analysis has a dedicated Category I CPT code (effective Jan 1, 2024) with ~99% U.S. coverage, and HeartFlow Plaque Analysis has a new Category I CPT code (effective Jan 1, 2026) with MAC coverage.
• Supported by strong clinical guidelines: CCTA is a Class 1, Level A test, and HeartFlow FFRCT Analysis is a Class 2a, Level B test for CAD diagnosis in certain patients.
• Operates with a highly scalable, capital-efficient commercial model, utilizing direct sales teams and cloud-based technology without requiring capital equipment purchases by customers.
• Leverages a proprietary database of approximately 110 million annotated CCTA images for continuous AI algorithm refinement and new product development.
• HeartFlow RoadMap Analysis improves CCTA interpretation times by approximately 25% and reduces variability between reviewing physicians by approximately 40%.
• Offers a better patient experience by using a single CCTA for all products, completing tests in approximately 20 minutes with significantly lower radiation exposure compared to traditional nuclear imaging tests.

Negatives

• Incurred significant net losses: $96.4 million in 2024 and $32.3 million in Q1 2025, with an accumulated deficit of $1.0 billion as of March 31, 2025.
• Highly dependent on a single product: HeartFlow FFRCT Analysis represented 99% of total revenue as of March 31, 2025, posing a concentration risk.
• Commercialization of HeartFlow Plaque Analysis is nascent, having generated minimal revenue to date.
• Preliminary estimated gross margin for Q2 2025 is expected to decrease to 74.5%-75.5% from 76.8% in Q2 2024, primarily due to investment in hiring and training production personnel.
• Cash and cash equivalents are projected to decrease from $109.8 million (March 31, 2025) to an estimated $80.2 million (June 30, 2025), partly due to bonus payments and IPO-related costs.
• Total operating expenses are expected to increase by 22% to 25% in Q2 2025 compared to Q2 2024, driven by growth initiatives and public company costs.
• Faces the risk that healthcare providers may be unwilling to change their standard practice regarding CAD evaluation, hindering adoption.
• Third-party payors, including government payors, may reduce reimbursement or change coding policies; for example, a proposed 15% reduction in Medicare reimbursement for HeartFlow FFRCT Analysis is included in the 2026 OPPS rule.
• Subject to risks associated with a concentrated customer base, despite no single customer accounting for 10% or more of revenue.
• Operates in a highly competitive environment with rapid technological change, facing competition from established medical technology companies and emerging AI-based platforms.
• Relies on third-party CT manufacturers and their continued support for standard output file formats, with potential for incompatibility or increased R&D expenses if formats change.
• Risks associated with the use and development of AI models, including potential for incorrect design/implementation, reliance on poor quality data, insufficient oversight, misuse, or unforeseen bugs/defects.
• The HeartFlow Platform has been subject to 116 MAUDE reports between 2017 and 2025, with 104 due to false negative results and 11 due to incorrect/imprecise results, indicating potential product defects.
• Subject to extensive and evolving regulatory requirements, with failure to receive or maintain clearances/approvals or comply with regulations potentially adversely affecting the business.
• The ability to use net operating losses (NOLs) and tax credits to offset future taxable income may be limited due to potential ownership changes (Section 382 of the Code).
• New investors in the IPO will experience immediate and substantial dilution of $14.10 per share based on the midpoint of the estimated price range.

Risks

• Incurred significant net losses since inception and expects additional substantial losses in the foreseeable future, may not achieve or sustain profitability.
• Revenue is currently generated almost entirely from the sales of only one product, HeartFlow FFRCT Analysis, making the company highly dependent on its success.
• If healthcare providers are unwilling to change their standard practice regarding the evaluation of CAD, the business, financial condition, results of operations, and prospects will be adversely affected.
• If third-party payors, including government payors, do not cover and provide adequate reimbursement for the HeartFlow Platform, or if existing payment amounts are reduced or coding changes (e.g., proposed 15% reduction in Medicare reimbursement for FFRCT Analysis in 2026), adoption will be negatively impacted.
• Faces risks associated with a concentrated customer base, where the loss of one customer could result in a disproportionate loss across accounts.
• Faces significant competition in an environment of rapid technological change, with competitors potentially developing more effective, accurate, reliable, cost-effective, or advanced products.
• The commercialization of the HeartFlow Plaque Analysis product is nascent, and the company may not achieve or maintain sufficient market acceptance or expected utilization levels.
• Faces risks associated with the use and development of artificial intelligence models, which may result in operational challenges, legal liability, reputational concerns, and competitive risks.
• If the company fails to properly manage future growth, its business could suffer.
• Business could be disrupted by catastrophic events, including natural disasters, power loss, telecommunications failure, software/hardware malfunctions, pandemics, cyberattacks, or supply chain disruptions (e.g., iodinated contrast media shortage).
• Dependence on information technology systems; any failure of these systems could harm the business and operating results.
• Networks and those of third-party service providers may become the target of bad actors or security breaches.
• Faces extensive regulatory requirements to bring products to market; failure to receive and maintain regulatory clearances/approvals or comply with medical device regulatory requirements could adversely affect the business.
• If unable to obtain and maintain sufficient intellectual property rights, or if the scope of rights is not sufficiently broad, third parties could develop and commercialize similar/identical technology and products.
• Credit agreement contains certain restrictions that may limit the ability to operate the business; raising additional capital through debt financing could further restrict operations.
• Operating results may fluctuate significantly, making future operating results difficult to predict and potentially causing results to fall below expectations.
• May require additional capital to support business growth, and this capital might not be available on favorable terms or at all, potentially diluting ownership of common stock.
• Subject to risks associated with currency fluctuations, which could impact results of operations.
• Ability to use net operating losses and tax credits to offset future taxable income and taxes may be subject to certain limitations (e.g., Section 382 of the Code).
• International operations subject the company to potentially adverse tax consequences.
• May face product liability claims that could result in costly litigation and significant liabilities, and may not be able to maintain adequate product liability insurance.
• The HeartFlow Platform may be subject to recalls (e.g., 116 MAUDE reports between 2017-2025, including 104 for false negatives).
• Off-label or other unlawful promotion of products could result in costly investigations and sanctions from the FDA and other regulatory bodies.
• Subject to numerous federal, state, and foreign healthcare fraud and abuse, compliance, transparency, and privacy laws and regulations; failure to comply could have an adverse effect.
• Subject to governmental export and import controls that could impair ability to compete in international markets.
• Future litigation against the company could be costly and time-consuming to defend.
• Open-source software licenses often impose unanticipated or unclear restrictions or could expose the company to litigation.
• Intellectual property rights do not necessarily address all potential threats to competitive advantage.
• Changes in patent law, precedents, and policies could diminish the value of patents.
• The terms of patents may not be sufficiently long to effectively protect products and business.
• Healthcare policy changes, including recently enacted legislation (e.g., OBBBA, IRA), could have an adverse effect on the business.
• Provisions in charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.

Future Outlook

HeartFlow expects to launch its HeartFlow PCI Planner product in 2026 as an integrated feature. The company anticipates HeartFlow Plaque Analysis to be included in updated cardiac imaging guidelines by EviCore by Evernorth, effective October 1, 2025, and a national Medicare payment rate for Plaque Analysis in the physician office setting is expected to take effect on January 1, 2026, if finalized. HeartFlow plans to continue investing in clinical evidence to support expanded indications for its platform, including asymptomatic risk prediction, and to further improve its AI algorithms and product features. The company believes its existing cash and cash equivalents, combined with the estimated net proceeds from the IPO, will be sufficient to fund planned operations for at least the next twelve months. While short-term gross margins may decrease due to investments in personnel, the company expects long-term gross margin expansion from AI automation. Selling, general and administrative expenses are projected to increase due to growth and public company costs, but are expected to decrease as a percentage of revenue. The American Medical Association may resurvey CPT codes for HeartFlow FFRCT Analysis as early as 2027 and HeartFlow Plaque Analysis as early as 2029, which could impact future reimbursement.

Management Comments

• "We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (CAD), a leading cause of death worldwide."
• "We believe that we are the most widely adopted AI-powered test for CAD."
• "We believe the differentiated accuracy and clinical utility of our Heartflow Platform, along with its ability to enhance workflows, will continue to support our growth and advance the CCTA + Heartflow pathway as the definitive standard for the non-invasive diagnosis and management of CAD."
• "We believe our Heartflow Platform delivers superior clinical utility and economic value to our customers and the broader healthcare system."
• "We believe the continued growth of our company will primarily be driven by [various success factors]."
• "Based on our current operating plan, we believe that the expected cash generated from revenue transactions with customers and our existing cash and cash equivalents will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months."

Industry Context

Cardiovascular disease, particularly CAD, remains the leading cause of death globally, highlighting a critical need for effective diagnostic and management solutions. Traditional non-invasive tests (NITs) like SPECT, echocardiography, and PET are often unreliable, leading to high rates of false negatives (20-50%) and false positives (up to 55%), which can result in missed diagnoses or unnecessary invasive procedures. Coronary Computed Tomography Angiography (CCTA) has gained prominence as a preferred first-line test, elevated to Class 1, Level A by AHA and ACC guidelines, with volumes growing at a 22% CAGR from 2018 to 2023. However, CCTA alone lacks the ability to quantify CAD severity, assess blood flow limitations, or characterize plaque composition. HeartFlow's AI-powered platform addresses these limitations by enhancing CCTA with actionable insights. The broader healthcare industry is experiencing a shift towards more precise, personalized cardiovascular care, driven by advancements in AI and imaging technologies. The regulatory landscape for AI in medical devices is rapidly evolving, with new guidance from bodies like the FDA and legislation such as the Colorado AI Act. New pharmaceutical treatments, such as GLP-1s, could also indirectly impact the market for non-invasive CAD tests by reducing plaque build-up. The increasing CMS reimbursement levels for hospital outpatient CCTA (104% increase in 2025) indicate a favorable trend for the underlying imaging modality that HeartFlow leverages.

Comparison to Industry Standards

• HeartFlow Platform is clinically validated to provide superior assessment of blood flow, plaque volume, and characterization compared to traditional non-invasive methods like SPECT, PET, and stress echocardiography.
• The PRECISE randomized controlled trial demonstrated that HeartFlow FFRCT Analysis was 78% more likely to identify patients in need of revascularization and showed a 69% reduction in unnecessary invasive coronary angiography (ICA) compared to a usual care pathway, leading to a 2x yield of ICA resulting in revascularization.
• The NXT trial showed HeartFlow FFRCT Analysis achieved a per-vessel accuracy of 86% compared to 65% for CCTA alone (p < 0.001) when measured against the invasive FFR reference standard.
• The PACIFIC trial indicated that HeartFlow FFRCT Analysis had the highest diagnostic performance for vessel-specific ischemia with an AUC (Area Under the Curve) of 0.94, surpassing PET (0.87), CTA (0.83), and SPECT (0.70) (p < 0.001 for all).
• The REVEALPLAQUE study validated HeartFlow Plaque Analysis against invasive intravascular ultrasound (IVUS), demonstrating 95% agreement for total coronary plaque volume.
• HeartFlow RoadMap Analysis, as shown in the SMART-CT study, reduces CCTA interpretation times by approximately 25% and increases consistency between reviewing physicians by approximately 40%.
• HeartFlow's single CCTA-based test, completed in approximately 20 minutes with significantly lower radiation exposure, offers a more efficient and patient-friendly alternative compared to nuclear imaging tests (SPECT and PET) that take multiple hours and require radioactive tracers.
• CMS reimbursement levels for hospital outpatient CCTA are set to increase by 104% in 2025, indicating a strong positive trend for the foundational imaging modality used by HeartFlow, contrasting with the historical challenges of reimbursement for novel technologies.

Management Changes

Corporate Governance

Legal Proceedings

• No legal, governmental, or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries, or proceedings are pending that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect on the company.
• The company has been selected for audit by the Internal Revenue Service for its 2022 tax year; the examination is in its early stages, and no tax adjustments are anticipated.

Related Party Transactions

• In January and March 2025, the company issued $98.3 million in 2025 Convertible Promissory Notes to various investors, including related parties such as Hayfin HeartFlow UK Limited, BCLS Fund III Investments, LP, Capricorn Entities, Timothy C. Barabe (director), Lonnie M. Smith (director), HCPCIV 1, LLC (affiliated with director Jeffrey C. Lightcap), U.S. Venture Partners Funds (affiliated with director Casey M. Tansey), and Vikram Verghese (CFO).
• On January 24, 2025, Hayfin HeartFlow UK Limited (an affiliate of Hayfin Services, LLP, the administrative agent for the 2024 Credit Agreement) converted $23.0 million of outstanding indebtedness under the 2024 Term Loan into 2025 Convertible Notes.
• In March 2023, the company completed a Series F and Series F-1 redeemable convertible preferred stock financing, issuing shares to various investors, including related parties such as BCLS Fund III Investments, LP, The Lonnie and Cheryl Smith Family Trust (affiliated with director Lonnie M. Smith), Hayfin HeartFlow UK Limited, HCPCIV 1, LLC, Wellington Entities, U.S. Venture Partners Funds, Capricorn Entities, The Schiehallion Fund Limited, William C. Weldon (director), and Charles A. Taylor, Jr., Ph.D. (director).
• From September to December 2022, the company issued $40.0 million in 2022 Convertible Promissory Notes to investors, including related parties such as The Lonnie and Cheryl Smith Family Trust, Hayfin HeartFlow UK Limited, HCPCIV 1, LLC, and William C. Weldon, which converted into Series F-1 preferred stock in March 2023.
• The company is party to an amended and restated investors rights agreement with purchasers of its outstanding redeemable convertible preferred stock, including directors and 5%+ holders, which will terminate upon the completion of this offering.
• The company is party to an amended and restated voting agreement with certain stockholders, including directors and 5%+ holders, which will terminate upon the completion of this offering.
• The company is party to an amended and restated right of first refusal and co-sale agreement with certain stockholders, including directors and 5%+ holders, which will terminate upon the completion of this offering.
• Management rights letters were entered into with certain preferred stock purchasers, including Wellington Entities, U.S. Venture Partners X, L.P., and Baillie Gifford Funds, granting management consultation rights, which will terminate upon the completion of this offering.
• A letter agreement with BCLS Fund III Investments, LP granted a board observer right, which will terminate upon the completion of this offering.
• A letter agreement with the Capricorn Entities granted a board observer right, which will terminate upon the completion of this offering.
• On March 29, 2023, the company repurchased 102,739 shares of common stock from the Taylor Family Revocable Trust, a family trust held by Charles A. Taylor, Jr., Ph.D., one of its directors, for $855,150.00.
• Michael Smith, a relative of director Lonnie M. Smith, has been a non-executive employee since 2014, with his cash compensation not exceeding $300,000 in 2022, 2023, or 2024.

Stakeholder Impact

• Shareholders: New investors in the IPO will experience immediate and substantial dilution of $14.10 per share. Existing principal stockholders and management will collectively own approximately 52.9% of common stock post-offering, retaining significant control. The market price of common stock may be volatile.
• Employees: The company is implementing new equity incentive plans (2025 Performance Incentive Plan and 2025 Employee Stock Purchase Plan) and a senior leadership severance policy, which could enhance retention and motivation. However, competition for highly skilled technical personnel remains intense.
• Customers: The company's continued investment in product enhancements (e.g., PCI Planner, Plaque Analysis improvements) and workflow efficiencies aims to improve patient care and diagnostic accuracy. Potential changes in reimbursement policies could impact the cost-effectiveness for customers.
• Creditors: A portion of the 2024 Credit Agreement debt ($50.0 million or $55.0 million) will be repaid using IPO proceeds, reducing immediate debt obligations. However, the company will remain subject to restrictive covenants under the remaining debt.

Next Steps

• Complete the initial public offering and list common stock on the Nasdaq Global Select Market under the symbol HTFL.
• Repay $50.0 million (or $55.0 million) of the 2024 Credit Agreement indebtedness and pay approximately $6.2 million in related fees using IPO proceeds.
• Utilize the remainder of the net IPO proceeds to fund sales and marketing efforts, research and product development activities, and general corporate purposes.
• Launch HeartFlow PCI Planner in 2026 as an integrated feature to optimize revascularization strategies.
• Broaden market education efforts for HeartFlow Plaque Analysis as payor coverage increases, anticipating its inclusion in EviCore by Evernorth guidelines by October 1, 2025.
• Continue to evaluate new product opportunities and gather clinical evidence to support eventual regulatory approval, payor coverage, and commercialization for asymptomatic CAD patients.
• Invest in additional clinical evidence to extend technology leadership and expand the applicability of the HeartFlow Platform into new indications.
• Continue to train and improve AI algorithms to drive greater quality and efficiency and reduce manual involvement in the production process.
• Enhance existing product features for HeartFlow FFRCT Analysis and HeartFlow Plaque Analysis and develop additional workflow enhancements for customers.
• Monitor and respond to potential changes in Medicare reimbursement rates, particularly the proposed 15% reduction for HeartFlow FFRCT Analysis in the 2026 OPPS rule.
• Prepare for potential resurvey of CPT codes for HeartFlow FFRCT Analysis (as early as 2027) and HeartFlow Plaque Analysis (as early as 2029) by the American Medical Association.
• Ensure compliance with the Quality Management System Regulation Final Rule (QMSR) which becomes effective on February 2, 2026.

Key Dates

Recommendation

HeartFlow operates in a high-growth, innovative sector with a strong product, extensive clinical evidence, and established reimbursement for its flagship FFRCT Analysis. The large addressable market and potential for new products like Plaque Analysis and PCI Planner offer significant long-term upside. However, the company's substantial and increasing net losses, accumulated deficit, and projected cash burn, coupled with a reliance on a single product for most revenue and potential future reimbursement reductions, present considerable financial risks. The IPO will provide capital, but dilution for new investors is immediate and significant. A 'hold' recommendation reflects the promising technology and market opportunity balanced against the current financial challenges and execution risks in achieving profitability. Investors should monitor the adoption of new products, reimbursement stability, and progress towards reducing losses.

Keywords

Coronary Artery Disease, CAD, AI-powered diagnosis, FFRCT Analysis, Plaque Analysis, CCTA, Medical Technology, Cardiovascular Health, IPO, Healthcare Diagnostics, Artificial Intelligence, SEC Filing, HeartFlow, MedTech